Skip to main
MYGN
MYGN logo

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 30 analyst ratings
Hold
Strong Buy 20%
Buy 13%
Hold 47%
Sell 20%
Strong Sell 0%

Bulls say

Myriad Genetics Inc. has demonstrated strong growth potential with its Pharmacogenomics segment, which experienced a 14% year-over-year increase in 2024, bolstered by a notable 23% growth in its GeneSight product. The company’s prenatal testing services, including Prequel and Foresight, achieved a combined growth rate of 12% in the fourth quarter of 2024 and 17% for the entire fiscal year, indicating robust demand and potential for re-acceleration moving forward. Additionally, Myriad is poised for future growth opportunities, particularly with an anticipated expansion of its hereditary cancer screening test in the second half of 2025, alongside favorable market dynamics in hereditary testing and potential legislative developments in biomarker legislation.

Bears say

Myriad Genetics has encountered significant challenges that contribute to a negative outlook, including the loss of reimbursement from a private payer for its GeneSight product and changes to NCCN guideline language, both of which are expected to impact near-term revenue negatively. Additionally, the firm has struggled to maintain and develop relationships with payors, which are crucial for its operational performance, leaving it vulnerable to further declines as competition and technological advancements intensify. The stock has plummeted over 50% in the past six months, compounded by risks related to price erosion, lower-than-expected volume growth, and a slowdown in the unaffected population business due to prolonged EMR workflow conversions.

Myriad Genetics (MYGN) has been analyzed by 30 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 13% recommend Buy, 47% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 30 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.